Figure 5.

(a,b) Seahorse analysis of (a) extracellular acidification rate (ECAR) and (b) glycolysis, glycolytic capacity and glycolytic reserve in BMDM treated with 50, 100 or 250 µM BSA-conjugated palmitate or 250 µM BSA alone. (c,d) Seahorse analysis of (c) oxygen consumption rate (OCR) and (d) basal respiration, maximum respiration and spare respiratory capacity in BMDM treated as indicated. (e) Relative mRNA expression of inflammatory cytokines in BMDM treated with 250 µM BSA or BSA-conjugated palmitate in the presence and absence of 2-deoxyglucose (2-DG). Levels of IL-1β protein in the supernatant of BMDM treated with BSA or BSA-palmitate in the presence of absence of (f) 2-DG or (g) a HIF-1α inhibitor. Data are representative of 3 independent experiments and are expressed as mean ± s.e.m. *p < 0.05.